Edition:
India

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

14.85USD
2:29am IST
Change (% chg)

$-0.90 (-5.75%)
Prev Close
$15.75
Open
$15.70
Day's High
$15.70
Day's Low
$14.69
Volume
628,360
Avg. Vol
436,921
52-wk High
$16.81
52-wk Low
$3.53

Latest Key Developments (Source: Significant Developments)

Adverum Biotechnologies Reports Additional Clinical Data From First Cohort Of Optic Phase 1 Trial Of ADVM-022 Intravitreal Gene Therapy
Saturday, 11 Jan 2020 

Jan 11 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS ADDITIONAL CLINICAL DATA FROM FIRST COHORT OF OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD AT THE ATLANTIC COAST RETINA CLUB MACULA 20/20 ANNUAL MEETING.DATA FROM 1ST COHORT OF OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY SHOWED ZERO RESCUE INJECTIONS FOR ANY PATIENT.AS OF DEC 1, ADVM-022 CONTINUES TO BE WELL-TOLERATED IN FIRST COHORT WITH NO DRUG-RELATED OR PROCEDURE-RELATED SERIOUS ADVERSE EVENTS.LOW-GRADE INFLAMMATION WAS REPORTED IN ALL 6 PATIENTS AND WAS GENERALLY MILD TO MODERATE AND RESPONSIVE TO STEROID EYE DROPS.  Full Article

Adverum Biotechnologies Q2 Loss Per Share $0.23
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.23.Q2 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.  Full Article

Adverum Biotechnologies Reports Q1 Loss Per Share $0.23
Thursday, 9 May 2019 

May 8 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.23.Q1 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.EXPECTS QUARTER-END CASH POSITION TO FUND OPERATIONS INTO 2021..ADVERUM EXPECTS THIS QUARTER-END CASH POSITION TO FUND OPERATIONS INTO 2021.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $189.5 MILLION AS OF MARCH 31, 2019.  Full Article

Adverum Biotechnologies Provides Clinical Program Update On Advm-022 Gene Therapy For Wet AMD
Monday, 15 Apr 2019 

April 15 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES CLINICAL PROGRAM UPDATE ON ADVM-022 GENE THERAPY FOR WET AMD.ADVERUM BIOTECHNOLOGIES INC - CLINICAL HOLD UNTIL ADDITIONAL CMC INFORMATION IS REVIEWED BY FDA.ADVERUM BIOTECHNOLOGIES INC - INDEPENDENT DMC REVIEW OF SAFETY DATA FROM FIRST COHORT OF SIX PATIENTS WITH NO SAES OR DLTS.ADVERUM BIOTECHNOLOGIES INC - ADVERUM PLANS TO PRESENT 24-WEEK DATA FROM FIRST COHORT OF PATIENTS AT SCIENTIFIC MEETING IN 2H19.ADVERUM BIOTECHNOLOGIES - INDEPENDENT DATA MONITORING COMMITTEE (DMC) DETERMINED THAT ENROLLMENT AND DOSING OF PATIENTS IN SECOND COHORT COULD PROCEED.ADVERUM - RECEIVED NOTIFICATION FROM FDA IN EARLY APRIL REQUESTING ADDITIONAL CMC INFORMATION AND REQUIREMENTS ON ADVM-022 MANUFACTURING PROCESS.ADVERUM BIOTECHNOLOGIES INC - FDA HAS PLACED COMPANY'S IND ON CLINICAL HOLD UNTIL AGENCY HAS REVIEWED ADVERUM'S RESPONSE.  Full Article

Adverum Biotechnologies Reports Fourth Quarter 2018 Financial Results
Thursday, 7 Mar 2019 

March 6 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.25.Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.EXPECTS YEAR-END CASH POSITION TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURES INTO 2021.ON TRACK TO PROVIDE AN ENROLLMENT UPDATE IN FIRST HALF OF 2019 ON OPTIC PHASE 1 CLINICAL TRIAL OF ADVM-022.ADVERUM BIOTECHNOLOGIES - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $205.1 MILLION AS OF DEC 31, 2018 VERSUS $217.9 MILLION AS OF SEPT 30, 2018.QTRLY REVENUE, CONSISTING OF REVENUE FROM COLLABORATIVE RESEARCH, WAS $0.1 MILLION VERSUS $0.5 MILLION.  Full Article

Adverum Biotechnologies Provides 2019 Outlook
Monday, 7 Jan 2019 

Jan 6 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES 2019 OUTLOOK.ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $217.9 MILLION AS OF SEPTEMBER 30, 2018.ADVERUM BIOTECHNOLOGIES INC - ADVERUM EXPECTS THIS QUARTER-END CASH POSITION TO FUND OPERATIONS AT LEAST THROUGH FIRST HALF OF 2020.ADVERUM BIOTECHNOLOGIES INC - TO PROVIDE AN UPDATE ON ENROLLMENT FROM OPTIC PHASE 1 CLINICAL TRIAL IN FIRST HALF OF 2019.ADVERUM BIOTECHNOLOGIES INC - TO PROVIDE INTERIM DATA ON THREE COHORTS FROM OPTIC PHASE 1 CLINICAL TRIAL BY Q1 OF 2020.ADVERUM BIOTECHNOLOGIES INC - TO PROVIDE AN UPDATE ON RARE DISEASE PROGRAM'S PRECLINICAL DEVELOPMENT PLAN IN FIRST HALF OF 2019.  Full Article

Adverum Biotechnologies Q2 Loss Per Share $0.30
Thursday, 9 Aug 2018 

Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.30.Q2 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.REMAIN ON TRACK TO DELIVER ON GOALS IN SECOND HALF OF YEAR FOR THREE LEAD GENE THERAPIES.SECURED A NEW FACILITY TO OCCUPY IN SECOND HALF OF NEXT YEAR.  Full Article